CAS 252916-29-3 | TSU-68 | Orantinib (SU6668)
CAS 252916-29-3 | TSU-68 | Orantinib (SU6668)
CAS 252916-29-3 | TSU-68 | Orantinib (SU6668)
+
  • CAS 252916-29-3 | TSU-68 | Orantinib (SU6668)
  • CAS 252916-29-3 | TSU-68 | Orantinib (SU6668)
  • CAS 252916-29-3 | TSU-68 | Orantinib (SU6668)

CAS 252916-29-3 | TSU-68 | Orantinib (SU6668)

Name: Orantinib (SU6668) CAS: 252916-29-3 MF: C18H18N2O3 MW: 310.35 Purity: 98% Package: 100g;1kg;10kg; Made in China Worldwide Delivery

Categories:

Other Material Chemicals

Product introduction

Introduction and application of CAS 252916-29-3 Orantinib (SU6668)

 

Synonyms: 

1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-;

SU 6668(TSU-68);

(E)-3-(2,4-diMethyl-5-((2-oxoindolin-3-ylidene)Methyl)-1H-pyrrol-3-yl)propanoic acid;

3-[2,4-dimethyl-5-[(E)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid;

(Z)-3-(2,4-dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid;

 

 

Specification:

ITEMS

SPECIFICATION

CAS

252916-29-3

MF

C18H18N2O3

MW

310.35

Melting point

252-254 °C

Boiling point

590.5±50.0 °C(Predicted)

Density

1.306±0.06 g/cm3(Predicted)

Acidity coefficient

4?+-.0.10(Predicted)

Color

Orange to brown

Form

Powder

Storage condition

Store at RT

 

 

Use:

1.An orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. 

2.Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Ki values ​​of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively. Orantinib (TSU-68) has been shown to inhibit VEGFR2, PDGFRβ and FGFR1. Clinical studies have shown that orantinib has the activity of stabilizing disease progression after chemoembolization in advanced hepatocellular carcinoma.

 

 

production method: N/A

 

 

Package and transportation: Normal

Package: 100g;1kg;10kg;

Transportation: by courier/ by air/ by sea

Key words:

Related Products

Related Products

Inquiry

SUBMIT